icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Viral Kinetics Modeling to Predict cEVR and Aid in Dose Selection Decisions for Phase-2/3 Clinical Trials: ACH3102+ Sovaprevir, ACH2684
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
Atul Agarwal, Bao Zhang, Heather Robison, Lisa Robarge, Yongsen Zhao, Joanne Fabrycki, Dharaben Patel, Guangwei Yang, Mingjun Huang, James Hui, Hetal Kocinsky, Elizabeth Olek, Milind Deshpande Achillion Pharmaceuticals, Inc., New Haven, CT

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif